Results for secretagogues translation from English to Maltese

insulin secretagogues
segretagogi ta’ insulina

combination with insulin secretagogues
it-teħid flimkien ma’ sustanzi li jikkawża s-sekrezzjoni tal-insulina

hypoglycaemia in add-on therapy with insulin or insulin secretagogues
ipogliċemija f’terapija miżjuda mal-insulina jew ma’ sustanzi li jikkawżaw it-tnixxija tal-insulina

insulin and insulin secretagogues, such as sulphonylureas, cause hypoglycaemia.
insulina u sustanzi li jikkawżaw il-ħelsien tal-insulina, bħal sulphonylureas, jikkawżaw ipogliċemija.

like other insulin secretagogues, nateglinide is capable of producing hypoglycaemia.
bħal sekretagogi ta’ l-insulina oħrajn, nateglinide għandu l-ħila li jikkawża ipogliċemija.

trials investigating the combination with other insulin secretagogues and acarbose have not been
ma sarux studji kliniċi li jinvestigaw t- teħid tal- prodott flimkien ma 'prodotti oħra li jikkawżaw s- sekrezzjoni ta ’ l- insulina u ma ’ acarbose.

insulin and insulin secretagogues, such as sulphonylureas, may increase the risk of hypoglycaemia.
l-insulina u sekretagogi tal-insulina, bħal sulphonylureas, jistgħu jgħollu r-riskju ta' ipogliċemija.

19 trials investigating the combination with other insulin secretagogues and acarbose have not been performed.
ma sarux studji kliniċi li jinvestigaw t- teħid tal- prodott flimkien ma 'prodotti oħra li jikkawżaw s- sekrezzjoni ta ’ l- insulina u ma ’ acarbose.

the rate and severity of these symptoms did not differ from that seen with other oral insulin secretagogues.
ir- rata u l- gravità ta 'dawn is- sintomi ma kinux differenti minn dawk li dehru bi prodotti oħra li jikkawżaw is- sekrezzjoni ta ’ l- insulina, li jingħataw mill- ħalq.

use of repaglinide in case of secondary failure to insulin secretagogues has not been investigated in clinical trials.
l- użu ta ’ repaglinide f' każ ta 'falliment sekondarju għal sustanzi li jikkawżaw s- sekrezzjoni ta ’ l- insulina ma ġiex investigat fi studji kliniċi.

repaglinide closes atp-dependent potassium channels in the β -cell membrane via a target protein different from other secretagogues.
repaglinide jagħlaq il- kanali tal- potassju dipendenti fuq l- atp fil- membrana taċ- ċelloli β permezz ta 'proteina partikolari li hija differenti minn prodotti oħra li jikkawżaw is- sekrezzjoni ta ’ l- insulina.

nateglinide is a rapid, short-acting oral insulin secretagogue.
nateglinide huwa sekretagogu ta’ l-insulina orali li jaħdem malajr u fi żmien qasir.